ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 105 filers reported holding ALBIREO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $659,105 | -73.2% | 30,500 | -76.0% | 0.00% | – |
| Q3 2022 | $2,461,000 | +24.5% | 127,125 | +27.6% | 0.00% | – |
| Q2 2022 | $1,977,000 | -58.5% | 99,594 | -37.6% | 0.00% | -100.0% |
| Q1 2022 | $4,761,000 | +28.2% | 159,616 | +0.1% | 0.00% | – |
| Q4 2021 | $3,714,000 | -43.0% | 159,496 | -23.7% | 0.00% | – |
| Q3 2021 | $6,518,000 | +7.1% | 208,922 | +20.8% | 0.00% | – |
| Q2 2021 | $6,086,000 | +45.4% | 172,998 | +45.7% | 0.00% | – |
| Q1 2021 | $4,185,000 | -40.3% | 118,727 | -36.5% | 0.00% | – |
| Q4 2020 | $7,008,000 | -65.1% | 186,846 | -69.0% | 0.00% | -100.0% |
| Q3 2020 | $20,091,000 | +766.7% | 602,072 | +587.9% | 0.00% | – |
| Q2 2020 | $2,318,000 | +211.1% | 87,517 | +92.3% | 0.00% | – |
| Q1 2020 | $745,000 | +153.4% | 45,500 | +209.5% | 0.00% | – |
| Q3 2019 | $294,000 | -7.0% | 14,700 | +50.0% | 0.00% | – |
| Q1 2019 | $316,000 | -69.1% | 9,800 | -68.8% | 0.00% | – |
| Q1 2018 | $1,023,000 | – | 31,415 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |